In the BioHarmony Drug Report Database

"Preview" Icon

Brivaracetam

Briviact, Briviact (in Italy: Nubriveo) (brivaracetam) is a small molecule pharmaceutical. Brivaracetam was first approved as Briviact on 2016-01-13. It is used to treat seizures in the USA. It has been approved in Europe to treat epilepsy. The pharmaceutical is active against synaptic vesicle glycoprotein 2A. Briviact’s patents are valid until 2030-04-09 (FDA).

 

Trade Name

 

Briviact (in Italy: Nubriveo)
 

Common Name

 

brivaracetam
 

ChEMBL ID

 

CHEMBL607400
 

Indication

 

epilepsy, seizures
 

Drug Class

 

Nootropes (piracetam type)

Image (chem structure or protein)

Brivaracetam structure rendering